Mankind Pharma, renowned for its Prega News pregnancy test kit, is intensifying its efforts in the women’s healthcare and fertility sectors. The pharmaceutical giant boasts a robust portfolio encompassing pivotal products such as Unwanted-72, Nufol, and Dydroboon, aimed at addressing various aspects of women’s health and fertility challenges.
In a strategic move to bolster its market position, Mankind Pharma recently completed the acquisition of Bharat Serums and Vaccines Limited (BSV) from Advent International, amounting to approximately Rs 13,630 crores. BSV’s extensive lineup, spanning Women’s Health, Fertility, and Critical Care, is expected to synergize effectively with Mankind Pharma’s expansion strategies.
Rajeev Juneja, Vice-chairman and Managing Director of Mankind Pharma Ltd., expressed optimism about the acquisition’s implications, stating, “BSV’s integration will enhance our footprint in India’s women’s health and fertility segments, tapping into significant growth opportunities both domestically and globally.” He emphasized the strategic fit of BSV’s Specialty R&D Tech Platforms and diverse product portfolio with Mankind Pharma’s growth trajectory.
Beyond its recent acquisition, Mankind Pharma maintains a diverse array of women’s health offerings including Dutan for menstrual disorders, Clear Gel for vaginal hygiene, and nutritional supplements like Fertisure-F and Fertisure-M supporting fertility in women and men respectively. This comprehensive lineup has solidified Mankind Pharma’s leadership in India’s evolving women’s health and fertility landscape.
The Indian women’s healthcare market is poised for substantial growth, driven by heightened awareness and rising infertility rates. Grand View Research estimates the market to have reached approximately ₹31,000 crores in 2023, projecting a compound annual growth rate (CAGR) of 11.5% from 2024 to 2030. Globally, the market is anticipated to soar to ₹3,40,000 crores by 2028, growing at a CAGR of 9.8% from 2023, as per MarketsandMarkets.
In the fertility sector, Market Research Future values the Indian market at ₹2,360 crores in 2023, with expectations of a CAGR of 12.2% through 2028. Globally, the fertility market is forecasted to expand to ₹2,71,000 crores by 2027, with a CAGR of 10.2% from 2022, according to Global Market Insights.
Analysts underscore Mankind Pharma’s prowess in manufacturing complex molecules such as Dydrogesterone, underscoring its competitive edge in the women’s health segment. Tushar Manudhane and Akash Manish Dobhada from Motilal Oswal Financial Services highlighted, “The company’s adeptness with Dydroboon has yielded robust sales, contributing significantly to its financial performance.”
With a strong financial trajectory, Mankind Pharma has demonstrated impressive growth, achieving a turnover increase from ₹6,400 crores to ₹10,550 crores over the past five years. The company has maintained a consistent double-digit growth rate, reflecting a five-year CAGR of 13%.
The expanding market dynamics coupled with Mankind Pharma’s strategic acquisitions and product innovation efforts position the company favorably in the competitive landscape of women’s health and fertility markets.
Related Links:
